way 100135 has been researched along with Cerebral Infarction, Middle Cerebral Artery in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, K; Egashira, N; Fujiwara, M; Hayakawa, K; Ikeda, T; Iwasaki, K; Mishima, K | 1 |
| Abe, K; Egashira, N; Fujioka, M; Fujiwara, M; Hasebe, N; Hayakawa, K; Hazekawa, M; Iwasaki, K; Liu, AX; Mishima, K; Nozako, M; Ogata, A | 1 |
2 other study(ies) available for way 100135 and Cerebral Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism.
Topics: Animals; Arachidonic Acids; Cannabidiol; Cerebral Infarction; Cerebrovascular Circulation; Endocannabinoids; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Piperazines; Polyunsaturated Alkamides; Receptor, Serotonin, 5-HT1A; Resorcinols; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists | 2005 |
Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance.
Topics: Analysis of Variance; Animals; Behavior, Animal; Body Temperature; Cannabidiol; Cerebral Infarction; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Dronabinol; Drug Administration Schedule; Drug Interactions; Drug Tolerance; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Piperazines; Piperidines; Pyrazoles; Rimonabant; Serotonin Antagonists; Time Factors | 2007 |